US equities
|
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Altimmune, Inc. - Common Stock
(NQ:
ALT
)
1.330
-0.080 (-5.67%)
Delayed Quote
Updated: 4:00 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Altimmune, Inc. - Common Stock
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >
Altimmune's Intranasal COVID-19 Vaccine Candidate Neutralizes South African Variant, Animal Study Shows
↗
May 26, 2021
Altimmune Inc (NASDAQ: ALT) has announced new results from a preclinical study of AdCOVID, the company's vaccine candidate. Data demonstrated that the vaccine...
Via
Benzinga
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing
↗
May 26, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:...
Via
Benzinga
Looking Into Altimmune's Return On Capital Employed
↗
May 17, 2021
During Q1, Altimmune's (NASDAQ:ALT) reported sales totaled $837.52 thousand. Despite a 38.25% in earnings, the company posted a loss of $14.86 million. Altimmune collected $2.31...
Via
Benzinga
52 Biggest Movers From Yesterday
↗
May 25, 2021
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares climbed 72% to close at $10.25 on Monday after the company reported the FDA approval of IND application for CpG-STAT3siRNA,...
Via
Benzinga
ALTIMMUNE INC (ALT) Q1 2021 Earnings Call Transcript
↗
May 17, 2021
ALT earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Altimmune Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
↗
May 11, 2021
On Tuesday, Altimmune stock received a positive adjustment to its Relative Strength Rating, from 78 to 86. The biopharma stock is worth watching.
Via
Investor's Business Daily
Earnings Scheduled For May 17, 2021
↗
May 17, 2021
Companies Reporting Before The Bell • Hycroft Mining Holding (NASDAQ:HYMC) is estimated to report earnings for its first quarter. • U.S. Well Services (NASDAQ:...
Via
Benzinga
Altimmune's Intranasal COVID-19 Vaccine Candidate Shows Sterilizing Immunity After Single Dose
↗
May 10, 2021
Altimmune Inc (NASDAQ: ALT) has announced positive results from a preclinical study evaluating its intranasal COVID-19 vaccine candidate, AdCOVID, in a SARS-...
Via
Benzinga
Could AstraZeneca's Nasal COVID Vaccine Development Zap Altimmune's Prospects?
↗
April 10, 2021
The short answer: It depends.
Via
The Motley Fool
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >